Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin

Progress in Biophysics and Molecular Biology

Volumn 117, Issue 2-3, 2015, Pages 225-231

  Lam, Kwok Ho ^a   Yao, Guorui ^a   Jin, Rongsheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Botulinum neurotoxin; Botulism; Host pathogen recognition; Protein complex; Synaptic vesicle glycoprotein 2; Synaptotagmin

Indexed keywords

BOTULINUM TOXIN; MEMBRANE PROTEIN; NEUROTOXIN; PROTEIN BINDING;

BINDING SITE; BIOLOGICAL MODEL; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; MOLECULAR MODEL; SYNAPSE; ULTRASTRUCTURE;

BINDING SITES; BOTULINUM TOXINS; COMPUTER SIMULATION; MEMBRANE GLYCOPROTEINS; MODELS, CHEMICAL; MODELS, MOLECULAR; MODELS, NEUROLOGICAL; NEUROTOXINS; PROTEIN BINDING; SYNAPSES;

EID: 84938957245     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.02.004     Document Type: Review

References (52)

1. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
2. Bajjalieh S.M., Peterson K., Shinghal R., Scheller R.H. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 1992, 257:1271-1273.
3. Barash J.R., Arnon S.S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 2014, 209:183-191.
4. Benoit R.M., Frey D., Hilbert M., Kevenaar J.T., Wieser M.M., Stirnimann C.U., McMillan D., Ceska T., Lebon F., Jaussi R., Steinmetz M.O., Schertler G.F., Hoogenraad C.C., Capitani G., Kammerer R.A. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 2014, 505:108-111.
5. Bercsenyi K., Schmieg N., Bryson J.B., Wallace M., Caccin P., Golding M., Zanotti G., Greensmith L., Nischt R., Schiavo G. Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus. Science 2014, 346:1118-1123.
6. Berntsson R.P., Peng L., Dong M., Stenmark P. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 2013, 4:2058.
7. Berntsson R.P., Peng L., Svensson L.M., Dong M., Stenmark P. Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II. Structure 2013, 21:1602-1611.
8. Bigalke H. Botulinum toxin: application, safety, and limitations. Curr. Top. Microbiol. Immunol. 2013, 364:307-317.
9. Bigalke H., Rummel A. Medical aspects of toxin weapons. Toxicology 2005, 214:210-220.
10. Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 1990, 265:9153-9158.
11. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., Sudhof T.C., Niemann H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
12. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444:1096-1100.
13. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell. 2008, 19:5226-5237.
14. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
15. Dover N., Barash J.R., Hill K.K., Xie G., Arnon S.S. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. 2014, 209:192-202.
16. Feany M.B., Lee S., Edwards R.H., Buckley K.M. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 1992, 70:861-867.
17. Fernandez-Chacon R., Konigstorfer A., Gerber S.H., Garcia J., Matos M.F., Stevens C.F., Brose N., Rizo J., Rosenmund C., Sudhof T.C. Synaptotagmin I functions as a calcium regulator of release probability. Nature 2001, 410:41-49.
18. Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 2009, 48:5631-5641.
19. Fujinaga Y., Sugawara Y., Matsumura T. Uptake of botulinum neurotoxin in the intestine. Curr. Top. Microbiol. Immunol. 2013, 364:45-59.
20. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 1982, 46:86-94.
21. Ginalski K., Venclovas C., Lesyng B., Fidelis K. Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett. 2000, 482:119-124.
22. Gu S., Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol. 2013, 364:21-44.
23. Gu S., Rumpel S., Zhou J., Strotmeier J., Bigalke H., Perry K., Shoemaker C.B., Rummel A., Jin R. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012, 335:977-981.
24. Jacky B.P., Garay P.E., Dupuy J., Nelson J.B., Cai B., Molina Y., Wang J., Steward L.E., Broide R.S., Francis J., Aoki K.R., Stevens R.C., Fernandez-Salas E. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog. 2013, 9:e1003369.
25. Janz R., Sudhof T.C. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 1999, 94:1279-1290.
26. Jin R., Rummel A., Binz T., Brunger A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
27. Karalewitz A.P., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J. Biol. Chem. 2012, 287:40806-40816.
28. Kumaran D., Eswaramoorthy S., Furey W., Navaza J., Sax M., Swaminathan S. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 2009, 386:233-245.
29. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
30. Lee K., Gu S., Jin L., Le T.T., Cheng L.W., Strotmeier J., Kruel A.M., Yao G., Perry K., Rummel A., Jin R. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013, 9:e1003690.
31. Lee K., Zhong X., Gu S., Kruel A.M., Dorner M.B., Perry K., Rummel A., Dong M., Jin R. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 2014, 344:1405-1410.
32. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
33. Mahrhold S., Strotmeier J., Garcia-Rodriguez C., Lou J., Marks J.D., Rummel A., Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem. J. 2013, 453:37-47.
34. Matsui T., Gu S., Lam K.H., Carter L.G., Rummel A., Mathews I.I., Jin R. Structural basis of the pH-dependent assembly of a botulinum neurotoxin complex. J. Mol. Biol. 2014, 426:3773-3782.
35. Montecucco C. How do tetanus and botulinum neurotoxins bind to neuronal membranes?. Trends Biochem. Sci. 1986, 11:314-317.
36. Peng L., Berntsson R.P., Tepp W.H., Pitkin R.M., Johnson E.A., Stenmark P., Dong M. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J. Cell. Sci. 2012, 125:3233-3242.
37. Peng L., Tepp W.H., Johnson E.A., Dong M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011, 7:e1002008.
38. Pierce E.J., Davison M.D., Parton R.G., Habig W.H., Critchley D.R. Characterization of tetanus toxin binding to rat brain membranes. Evidence for a high-affinity proteinase-sensitive receptor. Biochem. J. 1986, 236:845-852.
39. Rossetto O., Pirazzini M., Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 2014, 12:535-549.
40. Rummel A. Double receptor Anchorage of Botulinum neurotoxins accounts for their Exquisite neurospecificity. Curr. Top. Microbiol. Immunol. 2013, 364:61-90.
41. Rummel A., Eichner T., Weil T., Karnath T., Gutcaits A., Mahrhold S., Sandhoff K., Proia R.L., Acharya K.R., Bigalke H., Binz T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:359-364.
42. Rummel A., Hafner K., Mahrhold S., Darashchonak N., Holt M., Jahn R., Beermann S., Karnath T., Bigalke H., Binz T. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 2009, 110:1942-1954.
43. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
44. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
45. Schmitt J., Karalewitz A., Benefield D.A., Mushrush D.J., Pruitt R.N., Spiller B.W., Barbieri J.T., Lacy D.B. Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry 2010, 49:5200-5205.
46. Stenmark P., Dong M., Dupuy J., Chapman E.R., Stevens R.C. Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding. J. Mol. Biol. 2010, 397:1287-1297.
47. Strotmeier J., Gu S., Jutzi S., Mahrhold S., Zhou J., Pich A., Eichner T., Bigalke H., Rummel A., Jin R., Binz T. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol. Microbiol. 2011, 81:143-156.
48. Strotmeier J., Mahrhold S., Krez N., Janzen C., Lou J., Marks J.D., Binz T., Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014, 588:1087-1093.
49. Strotmeier J., Willjes G., Binz T., Rummel A. Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett. 2012, 586:310-313.
50. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7:693-699.
51. Whitemarsh R.C., Tepp W.H., Bradshaw M., Lin G., Pier C.L., Scherf J.M., Johnson E.A., Pellett S. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect. Immun. 2013, 81:3894-3902.
52. Willjes G., Mahrhold S., Strotmeier J., Eichner T., Rummel A., Binz T. Botulinum neurotoxin G binds synaptotagmin-II in a mode similar to that of serotype B: tyrosine 1186 and lysine 1191 cause its lower affinity. Biochemistry 2013, 52:3930-3938.